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WU Polyomavirus 
Infection in 
Children, Germany
To the Editor: The human polyo-
maviruses JC and BK are known to 
cause persisting infections, which are 
usually asymptomatic in immunocom-
petent patients but may lead to severe 
disease in those who are immunosup-
pressed (1). Recently, 2 novel viruses 
of the family Polyomaviridae were 
detected in respiratory samples and 
named KI (2) and WU polyomavirus 
(WUPyV) (3). To investigate the fre-
quency of WUPyV infections in Ger-
many, we examined nasopharyngeal 
samples from hospitalized children 
with acute respiratory diseases for 
WUPyV DNA.
The samples tested for WUPyV 
infection consisted of stored nasopha-
ryngeal aspirates (NPA) of hospitalized 
children at the Children’s Hospital, 
University of Würzburg. The samples 
had been received for routine screen-
ing of respiratory viruses from Janu-
ary 2002 through September 2005 and 
from January 2007 through July 2007. 
All samples were routinely tested for 
antigens of adenoviruses, inﬂ  uenza 
viruses A (ﬂ  uA) and B, parainﬂ  uenza 
viruses 1–3, and respiratory syncytial 
virus (RSV) by indirect immunoﬂ  uo-
rescence assays (Chemicon, Temec-
ula, CA, USA). Remaining NPA ma-
terial was stored at –20°C. DNA was 
extracted from the samples by using 
the High Pure Viral Nucleic Acid Kit 
(Roche, Mannheim, Germany) and 
stored at –70°C for further testing. All 
samples were also tested for human 
bocavirus (hBoV) DNA by PCR (4).
WUPyV PCR was performed by 
using the primer pair AG0048 and 
AG0049 described by Gaynor et al. 
(3). PCRs were conducted in a 50-μL 
volume consisting of 5-μL extract-
ed DNA, 1× Qiagen HotStar buffer 
(QIAGEN, Hilden, Germany), dNTPs 
at ﬁ  nal concentrations of 200 μmol/L 
each, 200 pmol of each primer, and 1.5 
U of HotStarTaq polymerase. The cy-
cling conditions were 50 cycles (94°C 
for 30 s, 53°C for 40 s, and 72°C for 1 
min) after a preheating step of 10 min 
at 95°C. All PCR products of positive 
reactions by agarose gel electropho-
resis with ethidium bromide staining 
were sequenced completely in both di-
rections for conﬁ  rmation of sequence 
speciﬁ  city. One negative control was 
extracted and ampliﬁ   ed for every 5 
NPA samples. A plasmid containing 
the cloned PCR product was used as 
positive control. The sensitivity of the 
WUPyV PCR was 8.8 copies per re-
action as determined by probit analy-
sis, which corresponds to 440 copies 
per mL of sample. The study was ap-
proved by the ethics committee of the 
medical faculty at the University of 
Würzburg.
During the study period, 1,326 
NPA of hospitalized children with fe-
brile respiratory tract diseases were re-
ceived for viral diagnostic evaluation. 
The median age of the patients was 
1.6 years (mean age 3.2 years; range 7 
days–22 years), and 58.4% were boys. 
DNA of 1,277 NPA from 1,085 chil-
dren was available for retrospective 
testing. Of these, 62 (4.9%) samples 
from 59 children were positive by 
WUPyV PCR and subsequent sequenc-
ing. The median age of the WUPyV-
positive children was 3.0 years (mean 
2.9 years; range 4 months–6.3 years) 
(Figure), and 57% were boys. Of the 
children with WUPyV-positive NPA, 
3.2% were >6 years of age, although 
children in this age group constituted 
15.7% of the total population. Infec-
tions with WUPyV were found year 
round, but most occurred in the win-
ter months. Yearly frequencies (Ju-
ly–June) of WUPyV-positive results 
varied from 3.2% to 8.5% during the 
observation period. These variations 
were not statistically signiﬁ  cant. In 34 
(54.8%) of the WUPyV-positive sam-
ples, co-infections with other respira-
tory viruses were detected, most fre-
quently with adenovirus (n = 10) and 
ﬂ  uA (n = 10), followed by hBoV (n = 
9) and RSV (n = 5). The co-infections 
included 4 triple infections (2 ﬂ  uA/
hBoV/WUPyV, 1 adenovirus/hBoV/
WUPyV, and 1 RSV/hBoV/WUPyV). 
Clinical data were available for 57 of 
the 62 WUPyV-positive NPA. A broad 
spectrum of both upper (45.6%) and 
lower (54.4%) respiratory tract diseas-
es was observed. The latter included 
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Figure. Age distribution of children with WU polyomavirus DNA–positive nasopharyngeal 
aspirates compared with the age distribution of the total study population. 
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bronchitis, wheezing bronchitis, and 
pneumonia.
In the context of the previous 
reports of WUPyV detection in Aus-
tralia and North America (3), our data 
suggest a worldwide distribution of 
WUPyV. Most of the WUPyV-pos-
itive children were <4 years of age, 
and WUPyV DNA was rarely found in 
children >6 years of age. This age dis-
tribution is compatible with WUPyV 
infection occurring in day nurseries 
and kindergartens. In keeping with the 
ﬁ  ndings of Gaynor et al. (3), we ob-
served a high number of co-infections. 
The true number of co-infections in 
our study is probably higher than the 
reported 53.2%  because we did not 
test for several respiratory pathogens, 
such as coronaviruses, rhinoviruses, 
enteroviruses, and the human metap-
neumovirus. Hypotheses to account 
for the detection of WUPyV in respi-
ratory samples include the following: 
WUPyV is a persisting asymptom-
atic virus that is detected by chance, 
WUPyV is a persisting virus that is 
reactivated by an inﬂ  ammatory pro-
cess, or WUPyV is a predisposing or 
aggravating factor of respiratory dis-
eases. Further studies are necessary to 
determine whether WUPyV is a hu-
man pathogen.
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Hepatitis E, Central 
African Republic  
To the Editor: Outbreaks of 
hepatitis E virus (HEV) have been 
documented in many geographic re-
gions and nonindustrialized countries 
(1–3); they have been primarily as-
sociated with fecal contamination 
of drinking water (4). In the Central 
African Republic (CAR), economic 
indicators (CAR ranks 172/177 coun-
tries on the 2006 United Nations De-
velopment Program Human Devel-
opment Index), political instability, 
geographic situation, a deteriorating 
health network, and a very poor epi-
demiologic surveillance system all 
contribute to the country’s epidemic 
susceptibility. 
In July 2002, Ministry of Health 
(MoH) and Médecins sans Frontières 
(MSF) teams working in the Begoua 
Commune Health Center, north of 
CAR’s capital Bangui, reported an 
increased number of patients from 
the Yembi I neighborhood who were 
showing signs of jaundice and ex-
treme fatigue. 
Patients suspected of having hepa-
titis E were deﬁ  ned as those with clini-
cal jaundice (yellow discoloration of 
the sclera) and symptoms of malaise, 
anorexia, abdominal pain, arthralgia, 
and fever. Conﬁ  rmed cases were those 
in which patients’ serum samples were 
positive for HEV immunoglobulin 
(Ig) M or IgG.
Initially, 16 pairs of serum and 
stool samples were collected from 
jaundiced patients. Fecal samples 
were stored at –20°C and sent to the 
National Reference Center of Enteri-
cally Transmitted Hepatitis, Hospital 
Val de Grâce (Paris, France) for HEV 
marker testing; serum samples were 
tested at the Bangui Pasteur Institute 
for yellow fewer (YF) IgM by MAC-
ELISA. 
The HEV epidemic was con-
ﬁ  rmed by the detection of HEV mark-
ers: HEV IgG (Enzyme Immuno As-
say, HEV, Abbott Laboratories, Abbott 
Park, IL, USA), HEV IgM (Abbott 
Laboratories), ampliﬁ   cation of RNA 
(5), and the absence of YF IgM. The 
HEV genome was detected in 4 of 
the fecal samples. Genotyping and 
sequencing showed that one of these 
was genotype 1, prevalent in Africa; 
the others were related to genotype 
2 (Mexico-like) (GenBank accession 
nos. DQ151640, DQ151640) (5,6).
Data suggest that the epidemic 
began in the Yembi I neighborhood, 
then spread to the rest of the Begoua 
commune and ﬁ  nally to Bangui or sur-
rounding areas (Figure). Of 715 sus-
pected HEV case-patients recorded in 
the MSF hospital between July 22 and 
October 25, 2002, 552 (77%) lived in 
the Begoua commune (271 in the Yem-
bi I neighborhood). The attack rate for 
the Begoua commune (20,080 inhab-
itants) was 2.7%. Of 351 suspected 
case-patients serologically tested for 
IgG and IgM anti-HEV antibodies, 
222 (63%) had IgM antibodies, in-
cluding 5/16 pregnant women (2.3% 
of all conﬁ  rmed cases). Most patients 
reported jaundice (97.5%) and cholu-
ria (95.1%);other reported symptoms 
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